airmanbc的个人主页 - 老虎社区

airmanbc

airmanbc

暂无个人介绍

IP属地：未知

13关注

6粉丝

0主题

0勋章

2021-12-07

I like the word “undisputed” 💪

Tesla Stock Price Target Raised to $1,000 at UBS. Here Is Why.

2021-11-19

👍

Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading

2021-11-19

👍

Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older

2021-11-19

I just got my Moderna booster 💪

Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older

2021-10-26

right

Missed Tesla? Here's The Next $1 Trillion Company

2021-10-21

👍

FDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing

2021-10-15

👍

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3582662259235370,"uuid":"3582662259235370","gmtCreate":1619568264754,"gmtModify":1706620618437,"name":"airmanbc","pinyin":"airmanbc","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":13,"tweetSize":67,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.95%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":606265454,"gmtCreate":1638886915646,"gmtModify":1638886923118,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"I like the word “undisputed” 💪","listText":"I like the word “undisputed” 💪","text":"I like the word “undisputed” 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606265454","repostId":"1195364731","repostType":4,"repost":{"id":"1195364731","pubTimestamp":1638885960,"share":"https://www.laohu8.com/m/news/1195364731?lang=&edition=full","pubTime":"2021-12-07 22:06","market":"us","language":"en","title":"Tesla Stock Price Target Raised to $1,000 at UBS. Here Is Why.","url":"https://stock-news.laohu8.com/highlight/detail?id=1195364731","media":"Barrons","summary":"Shares of Tesla were rebounding Tuesday after UBS raised its price target on the stock, calling the ","content":"<p>Shares of&nbsp;Tesla&nbsp;were rebounding Tuesday after UBS raised its price target on the stock, calling the electric-vehicle company the “undisputed leader” in the market.</p>\n<p>Analyst Patrick Hummel increased his price target to $1,000 from $725, saying global demand for electric vehicles will propel the company to continue beating expectations in 2022. Hummel maintained a Neutral rating on the stock.</p>\n<p>The electric-vehicle manufacturer had a rough Monday, with the stock closing at $1,009.01, slipping dangerously close to its third bear market of the year. Tesla (ticker:TSLA) was faring better Tuesday, with shares rising 3.7% to $1,046 in premarket trading.</p>\n<p>Of the 41 analysts surveyed by FactSet, 17 rate the stock at Buy or Overweight, 12 rate it a Hold, and 12 rate it a Sell. The average price target is $851.09.</p>\n<p>Tesla’s access to chips and batteries through vertical integration sets it apart from its competitors, helping the company cement market leadership with about 20% global EV share, the analyst said.</p>\n<p>“We’ve raised estimates sharply to reflect this undisputed leadership, however, current valuation fully reflects such steep curve,” Hummel wrote in a research note Tuesday.</p>\n<p>The title of Hummel’s research note on Tesla was: “Cementing leadership as EV market takes off: New $1,000 price target (from $725) – no rival to get even close to Tesla in 2022.”</p>\n<p>Hummel is forecasting Tesla’s car sales to grow from 894,000 in 2021 to 1.4 million in 2022, and reach 2.9 million by 2025, more than competitors&nbsp;BMW&nbsp;(BMW.DE) or&nbsp;Mercedes-Benz.He expects EVs in general to account for 50% of global car sales by 2030.</p>\n<p>A big part of Tesla’s advantage is the software’s scalability, which can drive a big revenue pool with even higher margins well beyond 2025, Hummel said.</p>\n<p>“Software is the next battleground in the global car industry, and no other carmaker is closer to monetize fully autonomous driving for everyday use, and the scalability of Tesla’s technology creates the biggest software-driven revenue opportunity in the industry,” he wrote.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock Price Target Raised to $1,000 at UBS. Here Is Why.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock Price Target Raised to $1,000 at UBS. Here Is Why.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-tsla-stock-price-target-raised-ubs-electric-vehicles-51638885474?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Tesla were rebounding Tuesday after UBS raised its price target on the stock, calling the electric-vehicle company the “undisputed leader” in the market.\nAnalyst Patrick Hummel increased his...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-tsla-stock-price-target-raised-ubs-electric-vehicles-51638885474?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-tsla-stock-price-target-raised-ubs-electric-vehicles-51638885474?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195364731","content_text":"Shares of Tesla were rebounding Tuesday after UBS raised its price target on the stock, calling the electric-vehicle company the “undisputed leader” in the market.\nAnalyst Patrick Hummel increased his price target to $1,000 from $725, saying global demand for electric vehicles will propel the company to continue beating expectations in 2022. Hummel maintained a Neutral rating on the stock.\nThe electric-vehicle manufacturer had a rough Monday, with the stock closing at $1,009.01, slipping dangerously close to its third bear market of the year. Tesla (ticker:TSLA) was faring better Tuesday, with shares rising 3.7% to $1,046 in premarket trading.\nOf the 41 analysts surveyed by FactSet, 17 rate the stock at Buy or Overweight, 12 rate it a Hold, and 12 rate it a Sell. The average price target is $851.09.\nTesla’s access to chips and batteries through vertical integration sets it apart from its competitors, helping the company cement market leadership with about 20% global EV share, the analyst said.\n“We’ve raised estimates sharply to reflect this undisputed leadership, however, current valuation fully reflects such steep curve,” Hummel wrote in a research note Tuesday.\nThe title of Hummel’s research note on Tesla was: “Cementing leadership as EV market takes off: New $1,000 price target (from $725) – no rival to get even close to Tesla in 2022.”\nHummel is forecasting Tesla’s car sales to grow from 894,000 in 2021 to 1.4 million in 2022, and reach 2.9 million by 2025, more than competitors BMW (BMW.DE) or Mercedes-Benz.He expects EVs in general to account for 50% of global car sales by 2030.\nA big part of Tesla’s advantage is the software’s scalability, which can drive a big revenue pool with even higher margins well beyond 2025, Hummel said.\n“Software is the next battleground in the global car industry, and no other carmaker is closer to monetize fully autonomous driving for everyday use, and the scalability of Tesla’s technology creates the biggest software-driven revenue opportunity in the industry,” he wrote.","news_type":1},"isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876567162,"gmtCreate":1637333054328,"gmtModify":1637333058832,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876567162","repostId":"1129693973","repostType":2,"repost":{"id":"1129693973","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637332940,"share":"https://www.laohu8.com/m/news/1129693973?lang=&edition=full","pubTime":"2021-11-19 22:42","market":"us","language":"en","title":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1129693973","media":"Tiger Newspress","summary":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US)","content":"<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p>\n<p>The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p>\n<p>Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p>\n<p>The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p>\n<p>Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129693973","content_text":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.\nThe report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"\nMoreover，Moderna, Inc. today announced that the U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876274245,"gmtCreate":1637327616774,"gmtModify":1637327616950,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876274245","repostId":"1138047553","repostType":4,"repost":{"id":"1138047553","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1},"isVote":1,"tweetType":1,"viewCount":465,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876274192,"gmtCreate":1637327527189,"gmtModify":1637327527331,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"I just got my Moderna booster 💪","listText":"I just got my Moderna booster 💪","text":"I just got my Moderna booster 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876274192","repostId":"1138047553","repostType":2,"repost":{"id":"1138047553","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1},"isVote":1,"tweetType":1,"viewCount":394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852888572,"gmtCreate":1635257254747,"gmtModify":1635257319078,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"right&nbsp;","listText":"right&nbsp;","text":"right","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852888572","repostId":"2178721405","repostType":4,"repost":{"id":"2178721405","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1635252117,"share":"https://www.laohu8.com/m/news/2178721405?lang=&edition=full","pubTime":"2021-10-26 20:41","market":"us","language":"en","title":"Missed Tesla? Here's The Next $1 Trillion Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2178721405","media":"Investors","summary":"The idea of an S&P 500 company hitting $1 trillion in market value used to seem impossible. But analysts insist another is on the way.","content":"<p>The idea of an S&amp;P 500 company hitting $1 trillion in market value used to seem impossible. But <b>Tesla</b> just did it — and analysts insist another is on the way.</p>\n<p>Analysts think <b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> should be the sixth S&amp;P 500 company valued at $1 trillion or more in 12 months or less, returning it to the trillion-dollar club. It would put the social networking giant in the same trillion-dollar league as <b>Apple</b>, <b>Microsoft</b>, <b>Alphabet</b>, <b>Amazon.com</b> and now Tesla.</p>\n<p>Shares of Facebook closed Monday at 328.69, down more than 14% from the 52-week high. That parked the company's valuation at $927 billion. But that was prior to the company late Monday topping third-quarter profit forecasts by 1.3% and jumping in after-hours trading to north of 337 a share. At this price, Facebook is worth $950 billion.</p>\n<p>It's only a matter of time until Facebook returns to the rarefied trillion-dollar air, though, say S&amp;P 500 analysts.</p>\n<h2>Trillion Dollar Redux For Facebook</h2>\n<p>Predicting Facebook will be a $1 trillion company is somewhat of an anticlimactic call.</p>\n<p>The company first closed above a trillion-dollar valuation back in July of this year. But since then, it's been on a rough run. Allegations of putting profit ahead of users' mental health, a high-profile outage and exposure to data limits at Apple knocked Facebook from its trillion-dollar perch. <b>Snap</b>'s recent disappointing third quarter and warning of problems tailoring social media ads on iPhones only fanned the worries.</p>\n<p>But analysts remain resolute on Facebook's future. They're calling for the stock to rally another 27% from Monday's close to 416.43 in 12 months, says data from S&amp;P Global Market Intelligence and MarketSmith. And if they're right, that would make Facebook a company valued at $1.17 billion. Should you buy Facebook stock now?</p>\n<p>Interestingly, if analysts are right, Facebook would supplant Tesla as the fifth most-valuable company in the S&amp;P 500. Analysts actually think Tesla's stock will drop 23% to 787.15. And if that's correct, it means Tesla would be worth just $779.3 billion, or a third less than what they think Facebook will be worth in 12 months. Should you buy Tesla stock now?</p>\n<h2>Who's Up In S&amp;P 500 After Facebook?</h2>\n<p>Facebook and Tesla might jockey for the trillion-dollar prize. But other than those two, are any other S&amp;P 500 stocks anywhere near a trillion? Nothing immediate.</p>\n<p>Warren Buffett's <b>Berkshire Hathaway</b> would appear next in line, as its market value is now $657.9 billion. Analysts, though, think even in 12 months time the company will be worth just $730.8 billion, falling shy of the trillion-dollar mark by nearly 40%. Also, it's not a particularly fast grower, so unlikely to surprise much to the upside. Analysts think Berkshire Hathaway's adjusted profit per share will only grow by 6.9% in 2022.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a></b> is a likely candidate in due time. The payment processing firm is already worth nearly $500 billion. And its adjusted profit per share is seen jumping 25% in 2022 to $7.26. Even so, analysts don't think it's going to happen anytime soon. Analysts are calling for the stock to inch up just 0.9% in 12 months.</p>\n<p>So it seems the world might need to be satisfied with five, or maybe six, trillion dollar companies for some time.</p>\n<h2>Analysts: The Most Valuable S&amp;P 500 Companies In The Future</h2>\n<p><i>Current and projected market values</i></p>\n<table>\n <thead>\n  <tr>\n   <th>Company</th>\n   <th>Ticker</th>\n   <th>Stock YTD % ch.</th>\n   <th>Market value now ($ trillions)</th>\n   <th>Analysts' 12-month market value target</th>\n   <th>Sector</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>Apple</td>\n   <td></td>\n   <td>12.0%</td>\n   <td>$2.5</td>\n   <td><b>$2.7</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Microsoft</td>\n   <td></td>\n   <td>38.5%</td>\n   <td>$2.3</td>\n   <td><b>$2.5</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Alphabet</td>\n   <td></td>\n   <td>56.8%</td>\n   <td>$1.8</td>\n   <td><b>$2.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Amazon.com</td>\n   <td></td>\n   <td>1.9%</td>\n   <td>$1.7</td>\n   <td><b>$2.1</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Facebook</td>\n   <td></td>\n   <td>20.3%</td>\n   <td>$0.9</td>\n   <td><b>$1.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Tesla</td>\n   <td></td>\n   <td>45.2%</td>\n   <td>$1.0</td>\n   <td><b>$0.8</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Berkshire Hathaway</td>\n   <td></td>\n   <td>25.5%</td>\n   <td>$0.7</td>\n   <td><b>$0.7</b></td>\n   <td>Financials</td>\n  </tr>\n  <tr>\n   <td>Visa</td>\n   <td></td>\n   <td>6.9%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Nvidia</td>\n   <td></td>\n   <td>77.4%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>JPMorgan Chase</td>\n   <td></td>\n   <td>34.5%</td>\n   <td>$0.5</td>\n   <td><b>$0.5</b></td>\n   <td>Financials</td>\n  </tr>\n </tbody>\n</table>\n<h5>Sources: IBD, S&amp;P Global Market Intelligence</h5>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Missed Tesla? Here's The Next $1 Trillion Company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMissed Tesla? Here's The Next $1 Trillion Company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-10-26 20:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>The idea of an S&amp;P 500 company hitting $1 trillion in market value used to seem impossible. But <b>Tesla</b> just did it — and analysts insist another is on the way.</p>\n<p>Analysts think <b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> should be the sixth S&amp;P 500 company valued at $1 trillion or more in 12 months or less, returning it to the trillion-dollar club. It would put the social networking giant in the same trillion-dollar league as <b>Apple</b>, <b>Microsoft</b>, <b>Alphabet</b>, <b>Amazon.com</b> and now Tesla.</p>\n<p>Shares of Facebook closed Monday at 328.69, down more than 14% from the 52-week high. That parked the company's valuation at $927 billion. But that was prior to the company late Monday topping third-quarter profit forecasts by 1.3% and jumping in after-hours trading to north of 337 a share. At this price, Facebook is worth $950 billion.</p>\n<p>It's only a matter of time until Facebook returns to the rarefied trillion-dollar air, though, say S&amp;P 500 analysts.</p>\n<h2>Trillion Dollar Redux For Facebook</h2>\n<p>Predicting Facebook will be a $1 trillion company is somewhat of an anticlimactic call.</p>\n<p>The company first closed above a trillion-dollar valuation back in July of this year. But since then, it's been on a rough run. Allegations of putting profit ahead of users' mental health, a high-profile outage and exposure to data limits at Apple knocked Facebook from its trillion-dollar perch. <b>Snap</b>'s recent disappointing third quarter and warning of problems tailoring social media ads on iPhones only fanned the worries.</p>\n<p>But analysts remain resolute on Facebook's future. They're calling for the stock to rally another 27% from Monday's close to 416.43 in 12 months, says data from S&amp;P Global Market Intelligence and MarketSmith. And if they're right, that would make Facebook a company valued at $1.17 billion. Should you buy Facebook stock now?</p>\n<p>Interestingly, if analysts are right, Facebook would supplant Tesla as the fifth most-valuable company in the S&amp;P 500. Analysts actually think Tesla's stock will drop 23% to 787.15. And if that's correct, it means Tesla would be worth just $779.3 billion, or a third less than what they think Facebook will be worth in 12 months. Should you buy Tesla stock now?</p>\n<h2>Who's Up In S&amp;P 500 After Facebook?</h2>\n<p>Facebook and Tesla might jockey for the trillion-dollar prize. But other than those two, are any other S&amp;P 500 stocks anywhere near a trillion? Nothing immediate.</p>\n<p>Warren Buffett's <b>Berkshire Hathaway</b> would appear next in line, as its market value is now $657.9 billion. Analysts, though, think even in 12 months time the company will be worth just $730.8 billion, falling shy of the trillion-dollar mark by nearly 40%. Also, it's not a particularly fast grower, so unlikely to surprise much to the upside. Analysts think Berkshire Hathaway's adjusted profit per share will only grow by 6.9% in 2022.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a></b> is a likely candidate in due time. The payment processing firm is already worth nearly $500 billion. And its adjusted profit per share is seen jumping 25% in 2022 to $7.26. Even so, analysts don't think it's going to happen anytime soon. Analysts are calling for the stock to inch up just 0.9% in 12 months.</p>\n<p>So it seems the world might need to be satisfied with five, or maybe six, trillion dollar companies for some time.</p>\n<h2>Analysts: The Most Valuable S&amp;P 500 Companies In The Future</h2>\n<p><i>Current and projected market values</i></p>\n<table>\n <thead>\n  <tr>\n   <th>Company</th>\n   <th>Ticker</th>\n   <th>Stock YTD % ch.</th>\n   <th>Market value now ($ trillions)</th>\n   <th>Analysts' 12-month market value target</th>\n   <th>Sector</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>Apple</td>\n   <td></td>\n   <td>12.0%</td>\n   <td>$2.5</td>\n   <td><b>$2.7</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Microsoft</td>\n   <td></td>\n   <td>38.5%</td>\n   <td>$2.3</td>\n   <td><b>$2.5</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Alphabet</td>\n   <td></td>\n   <td>56.8%</td>\n   <td>$1.8</td>\n   <td><b>$2.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Amazon.com</td>\n   <td></td>\n   <td>1.9%</td>\n   <td>$1.7</td>\n   <td><b>$2.1</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Facebook</td>\n   <td></td>\n   <td>20.3%</td>\n   <td>$0.9</td>\n   <td><b>$1.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Tesla</td>\n   <td></td>\n   <td>45.2%</td>\n   <td>$1.0</td>\n   <td><b>$0.8</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Berkshire Hathaway</td>\n   <td></td>\n   <td>25.5%</td>\n   <td>$0.7</td>\n   <td><b>$0.7</b></td>\n   <td>Financials</td>\n  </tr>\n  <tr>\n   <td>Visa</td>\n   <td></td>\n   <td>6.9%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Nvidia</td>\n   <td></td>\n   <td>77.4%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>JPMorgan Chase</td>\n   <td></td>\n   <td>34.5%</td>\n   <td>$0.5</td>\n   <td><b>$0.5</b></td>\n   <td>Financials</td>\n  </tr>\n </tbody>\n</table>\n<h5>Sources: IBD, S&amp;P Global Market Intelligence</h5>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","TSLA":"特斯拉","BRK.B":"伯克希尔B","AMZN":"亚马逊",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178721405","content_text":"The idea of an S&P 500 company hitting $1 trillion in market value used to seem impossible. But Tesla just did it — and analysts insist another is on the way.\nAnalysts think Facebook should be the sixth S&P 500 company valued at $1 trillion or more in 12 months or less, returning it to the trillion-dollar club. It would put the social networking giant in the same trillion-dollar league as Apple, Microsoft, Alphabet, Amazon.com and now Tesla.\nShares of Facebook closed Monday at 328.69, down more than 14% from the 52-week high. That parked the company's valuation at $927 billion. But that was prior to the company late Monday topping third-quarter profit forecasts by 1.3% and jumping in after-hours trading to north of 337 a share. At this price, Facebook is worth $950 billion.\nIt's only a matter of time until Facebook returns to the rarefied trillion-dollar air, though, say S&P 500 analysts.\nTrillion Dollar Redux For Facebook\nPredicting Facebook will be a $1 trillion company is somewhat of an anticlimactic call.\nThe company first closed above a trillion-dollar valuation back in July of this year. But since then, it's been on a rough run. Allegations of putting profit ahead of users' mental health, a high-profile outage and exposure to data limits at Apple knocked Facebook from its trillion-dollar perch. Snap's recent disappointing third quarter and warning of problems tailoring social media ads on iPhones only fanned the worries.\nBut analysts remain resolute on Facebook's future. They're calling for the stock to rally another 27% from Monday's close to 416.43 in 12 months, says data from S&P Global Market Intelligence and MarketSmith. And if they're right, that would make Facebook a company valued at $1.17 billion. Should you buy Facebook stock now?\nInterestingly, if analysts are right, Facebook would supplant Tesla as the fifth most-valuable company in the S&P 500. Analysts actually think Tesla's stock will drop 23% to 787.15. And if that's correct, it means Tesla would be worth just $779.3 billion, or a third less than what they think Facebook will be worth in 12 months. Should you buy Tesla stock now?\nWho's Up In S&P 500 After Facebook?\nFacebook and Tesla might jockey for the trillion-dollar prize. But other than those two, are any other S&P 500 stocks anywhere near a trillion? Nothing immediate.\nWarren Buffett's Berkshire Hathaway would appear next in line, as its market value is now $657.9 billion. Analysts, though, think even in 12 months time the company will be worth just $730.8 billion, falling shy of the trillion-dollar mark by nearly 40%. Also, it's not a particularly fast grower, so unlikely to surprise much to the upside. Analysts think Berkshire Hathaway's adjusted profit per share will only grow by 6.9% in 2022.\nVisa is a likely candidate in due time. The payment processing firm is already worth nearly $500 billion. And its adjusted profit per share is seen jumping 25% in 2022 to $7.26. Even so, analysts don't think it's going to happen anytime soon. Analysts are calling for the stock to inch up just 0.9% in 12 months.\nSo it seems the world might need to be satisfied with five, or maybe six, trillion dollar companies for some time.\nAnalysts: The Most Valuable S&P 500 Companies In The Future\nCurrent and projected market values\n\n\n\nCompany\nTicker\nStock YTD % ch.\nMarket value now ($ trillions)\nAnalysts' 12-month market value target\nSector\n\n\n\n\nApple\n\n12.0%\n$2.5\n$2.7\nInformation Technology\n\n\nMicrosoft\n\n38.5%\n$2.3\n$2.5\nInformation Technology\n\n\nAlphabet\n\n56.8%\n$1.8\n$2.2\nCommunication Services\n\n\nAmazon.com\n\n1.9%\n$1.7\n$2.1\nConsumer Discretionary\n\n\nFacebook\n\n20.3%\n$0.9\n$1.2\nCommunication Services\n\n\nTesla\n\n45.2%\n$1.0\n$0.8\nConsumer Discretionary\n\n\nBerkshire Hathaway\n\n25.5%\n$0.7\n$0.7\nFinancials\n\n\nVisa\n\n6.9%\n$0.6\n$0.6\nInformation Technology\n\n\nNvidia\n\n77.4%\n$0.6\n$0.6\nInformation Technology\n\n\nJPMorgan Chase\n\n34.5%\n$0.5\n$0.5\nFinancials\n\n\n\nSources: IBD, S&P Global Market Intelligence","news_type":1},"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853879081,"gmtCreate":1634793211465,"gmtModify":1634793211614,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853879081","repostId":"1115514997","repostType":4,"repost":{"id":"1115514997","pubTimestamp":1634771335,"share":"https://www.laohu8.com/m/news/1115514997?lang=&edition=full","pubTime":"2021-10-21 07:08","market":"us","language":"en","title":"FDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing","url":"https://stock-news.laohu8.com/highlight/detail?id=1115514997","media":"Bloomberg","summary":"Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be gi","content":"<ul>\n <li>Actions mean extra doses now allowed for all three U.S. shots</li>\n <li>Agency allows different shots to be given to bolster immunity</li>\n</ul>\n<p>The U.S. Food and Drug Administration cleared a path for millions more Americans to receive Covid-19 vaccine booster shots, as the nation looks to bolster its defenses and prevent another virus surge.</p>\n<p>The agency said in a&nbsp;statement&nbsp;on Wednesday that&nbsp;Moderna Inc.&nbsp;vaccine recipients 65 and over can receive a third shot, as can adults 18 and up who are at high risk of severe Covid or with frequent institutional or occupational exposure to the virus that causes the disease.</p>\n<p>Additionally, all J&amp;J recipients 18 and older are eligible for a booster shot at least two months after receiving their first dose.</p>\n<p>The agency also allowed each of the available Covid vaccines to be used as a booster dose for eligible individuals following completion of a primary vaccination with a different vaccine.</p>\n<p>The moves will mean the U.S. has a bigger toolkit to try to limit a potential winter virus rebound. The summer’s delta-variant fueled spike in infections helped increase urgency to make boosters available, and health officials across the U.S. are eager to forestall a rebound in cases that could cripple hospitals and disrupt work and school this winter.</p>\n<p>FDA officials indicated they would also move quickly to expand eligibility for booster shots as more data become available or if breakthrough cases start to rise in younger adults.</p>\n<p>“We will not hesitate to drop this age range as we see that that benefit clearly outweighs the risk,” said Peter Marks, the head of the agency’s Center for Biologics Evaluation and Research, during a media briefing following the announcement.</p>\n<p>The clearances came after a panel of expert advisers to the FDA unanimously backed the Moderna and J&amp;J booster regimens in two days of meetings last week. Regulators have now signed off on boosters for all three coronavirus vaccines available in the U.S.</p>\n<p>Last month, the FDA said people 65 and over and others who are at heightened risk of severe Covid were eligible for a booster dose of the vaccine developed by&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE.</p>\n<p>Moderna shares climbed 1% in after-hours trading in New York, while J&amp;J shares gained 0.4% and Pfizer shares rose 0.2%. U.S.-traded shares of Germany-based BioNTech gained 0.9%.</p>\n<p><b>Smaller Dose</b></p>\n<p>The Moderna booster shot authorized by the FDA is half the dose that is given in the initial two-shot series, and it should be given at least six months after the initial inoculation, regulators said.</p>\n<p>The FDA said that a single booster dose of the Pfizer vaccine may be given at least 6 months after completing the primary series to people 18 to 64 with frequent institutional or occupational exposure to the coronavirus.</p>\n<p>In permitting mixing and matching, the FDA is allowing J&amp;J vaccine recipients to receive an additional dose of any cleared vaccine after two months. Likewise, recipients of Moderna and Pfizer who are eligible for a booster would receive their booster, including J&amp;J’s shot, at least six months after their initial immunization regimen.</p>\n<p>Marks said during the call with reporters that different combinations produce different antibody levels in the short term, but it isn’t clear what that means in terms of actual long-term protection.</p>\n<p>Seen as a convenient, effective alternative to two-shot messenger RNA vaccines, J&amp;J’s single-shot immunization has seen far less use in the U.S., in part because it isn’t as effective. The drugmaker has also experienced manufacturing problems that limited the shot’s distribution.</p>\n<p>The decision to allow mixing will create greater flexibility and is beneficial to global public health, Paul Stoffels, J&amp;J’s chief scientific officer, said in a statement.</p>\n<p>Before the Moderna and J&amp;J booster shots can be administered, the Centers for Disease Control and Prevention’s Advisory Panel on Immunization Practices will make further recommendations about who should receive them. The panel is scheduled to discuss boosters on Thursday.</p>\n<p>The next big milestone for the U.S. immunization effort looms next week, when the FDA advisory panel is expected to weigh Pfizer’s proposed Covid vaccine for children ages 5 to 11. If authorized, it could begin to roll out to pediatricians’ offices and drugstores as soon as next month.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-21 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be given to bolster immunity\n\nThe U.S. Food and Drug Administration cleared a path for millions more ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","AZN":"阿斯利康","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","MRK":"默沙东","JNJ":"强生"},"source_url":"https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115514997","content_text":"Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be given to bolster immunity\n\nThe U.S. Food and Drug Administration cleared a path for millions more Americans to receive Covid-19 vaccine booster shots, as the nation looks to bolster its defenses and prevent another virus surge.\nThe agency said in a statement on Wednesday that Moderna Inc. vaccine recipients 65 and over can receive a third shot, as can adults 18 and up who are at high risk of severe Covid or with frequent institutional or occupational exposure to the virus that causes the disease.\nAdditionally, all J&J recipients 18 and older are eligible for a booster shot at least two months after receiving their first dose.\nThe agency also allowed each of the available Covid vaccines to be used as a booster dose for eligible individuals following completion of a primary vaccination with a different vaccine.\nThe moves will mean the U.S. has a bigger toolkit to try to limit a potential winter virus rebound. The summer’s delta-variant fueled spike in infections helped increase urgency to make boosters available, and health officials across the U.S. are eager to forestall a rebound in cases that could cripple hospitals and disrupt work and school this winter.\nFDA officials indicated they would also move quickly to expand eligibility for booster shots as more data become available or if breakthrough cases start to rise in younger adults.\n“We will not hesitate to drop this age range as we see that that benefit clearly outweighs the risk,” said Peter Marks, the head of the agency’s Center for Biologics Evaluation and Research, during a media briefing following the announcement.\nThe clearances came after a panel of expert advisers to the FDA unanimously backed the Moderna and J&J booster regimens in two days of meetings last week. Regulators have now signed off on boosters for all three coronavirus vaccines available in the U.S.\nLast month, the FDA said people 65 and over and others who are at heightened risk of severe Covid were eligible for a booster dose of the vaccine developed by Pfizer Inc. and BioNTech SE.\nModerna shares climbed 1% in after-hours trading in New York, while J&J shares gained 0.4% and Pfizer shares rose 0.2%. U.S.-traded shares of Germany-based BioNTech gained 0.9%.\nSmaller Dose\nThe Moderna booster shot authorized by the FDA is half the dose that is given in the initial two-shot series, and it should be given at least six months after the initial inoculation, regulators said.\nThe FDA said that a single booster dose of the Pfizer vaccine may be given at least 6 months after completing the primary series to people 18 to 64 with frequent institutional or occupational exposure to the coronavirus.\nIn permitting mixing and matching, the FDA is allowing J&J vaccine recipients to receive an additional dose of any cleared vaccine after two months. Likewise, recipients of Moderna and Pfizer who are eligible for a booster would receive their booster, including J&J’s shot, at least six months after their initial immunization regimen.\nMarks said during the call with reporters that different combinations produce different antibody levels in the short term, but it isn’t clear what that means in terms of actual long-term protection.\nSeen as a convenient, effective alternative to two-shot messenger RNA vaccines, J&J’s single-shot immunization has seen far less use in the U.S., in part because it isn’t as effective. The drugmaker has also experienced manufacturing problems that limited the shot’s distribution.\nThe decision to allow mixing will create greater flexibility and is beneficial to global public health, Paul Stoffels, J&J’s chief scientific officer, said in a statement.\nBefore the Moderna and J&J booster shots can be administered, the Centers for Disease Control and Prevention’s Advisory Panel on Immunization Practices will make further recommendations about who should receive them. The panel is scheduled to discuss boosters on Thursday.\nThe next big milestone for the U.S. immunization effort looms next week, when the FDA advisory panel is expected to weigh Pfizer’s proposed Covid vaccine for children ages 5 to 11. If authorized, it could begin to roll out to pediatricians’ offices and drugstores as soon as next month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824668787,"gmtCreate":1634308679503,"gmtModify":1634308679653,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/824668787","repostId":"2175143354","repostType":2,"isVote":1,"tweetType":1,"viewCount":419,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":876274192,"gmtCreate":1637327527189,"gmtModify":1637327527331,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"I just got my Moderna booster 💪","listText":"I just got my Moderna booster 💪","text":"I just got my Moderna booster 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876274192","repostId":"1138047553","repostType":2,"repost":{"id":"1138047553","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1},"isVote":1,"tweetType":1,"viewCount":394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876274245,"gmtCreate":1637327616774,"gmtModify":1637327616950,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876274245","repostId":"1138047553","repostType":4,"repost":{"id":"1138047553","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1},"isVote":1,"tweetType":1,"viewCount":465,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876567162,"gmtCreate":1637333054328,"gmtModify":1637333058832,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876567162","repostId":"1129693973","repostType":2,"repost":{"id":"1129693973","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637332940,"share":"https://www.laohu8.com/m/news/1129693973?lang=&edition=full","pubTime":"2021-11-19 22:42","market":"us","language":"en","title":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1129693973","media":"Tiger Newspress","summary":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US)","content":"<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p>\n<p>The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p>\n<p>Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p>\n<p>The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p>\n<p>Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129693973","content_text":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.\nThe report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"\nMoreover，Moderna, Inc. today announced that the U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853879081,"gmtCreate":1634793211465,"gmtModify":1634793211614,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853879081","repostId":"1115514997","repostType":4,"repost":{"id":"1115514997","pubTimestamp":1634771335,"share":"https://www.laohu8.com/m/news/1115514997?lang=&edition=full","pubTime":"2021-10-21 07:08","market":"us","language":"en","title":"FDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing","url":"https://stock-news.laohu8.com/highlight/detail?id=1115514997","media":"Bloomberg","summary":"Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be gi","content":"<ul>\n <li>Actions mean extra doses now allowed for all three U.S. shots</li>\n <li>Agency allows different shots to be given to bolster immunity</li>\n</ul>\n<p>The U.S. Food and Drug Administration cleared a path for millions more Americans to receive Covid-19 vaccine booster shots, as the nation looks to bolster its defenses and prevent another virus surge.</p>\n<p>The agency said in a&nbsp;statement&nbsp;on Wednesday that&nbsp;Moderna Inc.&nbsp;vaccine recipients 65 and over can receive a third shot, as can adults 18 and up who are at high risk of severe Covid or with frequent institutional or occupational exposure to the virus that causes the disease.</p>\n<p>Additionally, all J&amp;J recipients 18 and older are eligible for a booster shot at least two months after receiving their first dose.</p>\n<p>The agency also allowed each of the available Covid vaccines to be used as a booster dose for eligible individuals following completion of a primary vaccination with a different vaccine.</p>\n<p>The moves will mean the U.S. has a bigger toolkit to try to limit a potential winter virus rebound. The summer’s delta-variant fueled spike in infections helped increase urgency to make boosters available, and health officials across the U.S. are eager to forestall a rebound in cases that could cripple hospitals and disrupt work and school this winter.</p>\n<p>FDA officials indicated they would also move quickly to expand eligibility for booster shots as more data become available or if breakthrough cases start to rise in younger adults.</p>\n<p>“We will not hesitate to drop this age range as we see that that benefit clearly outweighs the risk,” said Peter Marks, the head of the agency’s Center for Biologics Evaluation and Research, during a media briefing following the announcement.</p>\n<p>The clearances came after a panel of expert advisers to the FDA unanimously backed the Moderna and J&amp;J booster regimens in two days of meetings last week. Regulators have now signed off on boosters for all three coronavirus vaccines available in the U.S.</p>\n<p>Last month, the FDA said people 65 and over and others who are at heightened risk of severe Covid were eligible for a booster dose of the vaccine developed by&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE.</p>\n<p>Moderna shares climbed 1% in after-hours trading in New York, while J&amp;J shares gained 0.4% and Pfizer shares rose 0.2%. U.S.-traded shares of Germany-based BioNTech gained 0.9%.</p>\n<p><b>Smaller Dose</b></p>\n<p>The Moderna booster shot authorized by the FDA is half the dose that is given in the initial two-shot series, and it should be given at least six months after the initial inoculation, regulators said.</p>\n<p>The FDA said that a single booster dose of the Pfizer vaccine may be given at least 6 months after completing the primary series to people 18 to 64 with frequent institutional or occupational exposure to the coronavirus.</p>\n<p>In permitting mixing and matching, the FDA is allowing J&amp;J vaccine recipients to receive an additional dose of any cleared vaccine after two months. Likewise, recipients of Moderna and Pfizer who are eligible for a booster would receive their booster, including J&amp;J’s shot, at least six months after their initial immunization regimen.</p>\n<p>Marks said during the call with reporters that different combinations produce different antibody levels in the short term, but it isn’t clear what that means in terms of actual long-term protection.</p>\n<p>Seen as a convenient, effective alternative to two-shot messenger RNA vaccines, J&amp;J’s single-shot immunization has seen far less use in the U.S., in part because it isn’t as effective. The drugmaker has also experienced manufacturing problems that limited the shot’s distribution.</p>\n<p>The decision to allow mixing will create greater flexibility and is beneficial to global public health, Paul Stoffels, J&amp;J’s chief scientific officer, said in a statement.</p>\n<p>Before the Moderna and J&amp;J booster shots can be administered, the Centers for Disease Control and Prevention’s Advisory Panel on Immunization Practices will make further recommendations about who should receive them. The panel is scheduled to discuss boosters on Thursday.</p>\n<p>The next big milestone for the U.S. immunization effort looms next week, when the FDA advisory panel is expected to weigh Pfizer’s proposed Covid vaccine for children ages 5 to 11. If authorized, it could begin to roll out to pediatricians’ offices and drugstores as soon as next month.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-21 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be given to bolster immunity\n\nThe U.S. Food and Drug Administration cleared a path for millions more ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","AZN":"阿斯利康","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","MRK":"默沙东","JNJ":"强生"},"source_url":"https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115514997","content_text":"Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be given to bolster immunity\n\nThe U.S. Food and Drug Administration cleared a path for millions more Americans to receive Covid-19 vaccine booster shots, as the nation looks to bolster its defenses and prevent another virus surge.\nThe agency said in a statement on Wednesday that Moderna Inc. vaccine recipients 65 and over can receive a third shot, as can adults 18 and up who are at high risk of severe Covid or with frequent institutional or occupational exposure to the virus that causes the disease.\nAdditionally, all J&J recipients 18 and older are eligible for a booster shot at least two months after receiving their first dose.\nThe agency also allowed each of the available Covid vaccines to be used as a booster dose for eligible individuals following completion of a primary vaccination with a different vaccine.\nThe moves will mean the U.S. has a bigger toolkit to try to limit a potential winter virus rebound. The summer’s delta-variant fueled spike in infections helped increase urgency to make boosters available, and health officials across the U.S. are eager to forestall a rebound in cases that could cripple hospitals and disrupt work and school this winter.\nFDA officials indicated they would also move quickly to expand eligibility for booster shots as more data become available or if breakthrough cases start to rise in younger adults.\n“We will not hesitate to drop this age range as we see that that benefit clearly outweighs the risk,” said Peter Marks, the head of the agency’s Center for Biologics Evaluation and Research, during a media briefing following the announcement.\nThe clearances came after a panel of expert advisers to the FDA unanimously backed the Moderna and J&J booster regimens in two days of meetings last week. Regulators have now signed off on boosters for all three coronavirus vaccines available in the U.S.\nLast month, the FDA said people 65 and over and others who are at heightened risk of severe Covid were eligible for a booster dose of the vaccine developed by Pfizer Inc. and BioNTech SE.\nModerna shares climbed 1% in after-hours trading in New York, while J&J shares gained 0.4% and Pfizer shares rose 0.2%. U.S.-traded shares of Germany-based BioNTech gained 0.9%.\nSmaller Dose\nThe Moderna booster shot authorized by the FDA is half the dose that is given in the initial two-shot series, and it should be given at least six months after the initial inoculation, regulators said.\nThe FDA said that a single booster dose of the Pfizer vaccine may be given at least 6 months after completing the primary series to people 18 to 64 with frequent institutional or occupational exposure to the coronavirus.\nIn permitting mixing and matching, the FDA is allowing J&J vaccine recipients to receive an additional dose of any cleared vaccine after two months. Likewise, recipients of Moderna and Pfizer who are eligible for a booster would receive their booster, including J&J’s shot, at least six months after their initial immunization regimen.\nMarks said during the call with reporters that different combinations produce different antibody levels in the short term, but it isn’t clear what that means in terms of actual long-term protection.\nSeen as a convenient, effective alternative to two-shot messenger RNA vaccines, J&J’s single-shot immunization has seen far less use in the U.S., in part because it isn’t as effective. The drugmaker has also experienced manufacturing problems that limited the shot’s distribution.\nThe decision to allow mixing will create greater flexibility and is beneficial to global public health, Paul Stoffels, J&J’s chief scientific officer, said in a statement.\nBefore the Moderna and J&J booster shots can be administered, the Centers for Disease Control and Prevention’s Advisory Panel on Immunization Practices will make further recommendations about who should receive them. The panel is scheduled to discuss boosters on Thursday.\nThe next big milestone for the U.S. immunization effort looms next week, when the FDA advisory panel is expected to weigh Pfizer’s proposed Covid vaccine for children ages 5 to 11. If authorized, it could begin to roll out to pediatricians’ offices and drugstores as soon as next month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824668787,"gmtCreate":1634308679503,"gmtModify":1634308679653,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/824668787","repostId":"2175143354","repostType":2,"isVote":1,"tweetType":1,"viewCount":419,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606265454,"gmtCreate":1638886915646,"gmtModify":1638886923118,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"I like the word “undisputed” 💪","listText":"I like the word “undisputed” 💪","text":"I like the word “undisputed” 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606265454","repostId":"1195364731","repostType":4,"repost":{"id":"1195364731","pubTimestamp":1638885960,"share":"https://www.laohu8.com/m/news/1195364731?lang=&edition=full","pubTime":"2021-12-07 22:06","market":"us","language":"en","title":"Tesla Stock Price Target Raised to $1,000 at UBS. Here Is Why.","url":"https://stock-news.laohu8.com/highlight/detail?id=1195364731","media":"Barrons","summary":"Shares of Tesla were rebounding Tuesday after UBS raised its price target on the stock, calling the ","content":"<p>Shares of&nbsp;Tesla&nbsp;were rebounding Tuesday after UBS raised its price target on the stock, calling the electric-vehicle company the “undisputed leader” in the market.</p>\n<p>Analyst Patrick Hummel increased his price target to $1,000 from $725, saying global demand for electric vehicles will propel the company to continue beating expectations in 2022. Hummel maintained a Neutral rating on the stock.</p>\n<p>The electric-vehicle manufacturer had a rough Monday, with the stock closing at $1,009.01, slipping dangerously close to its third bear market of the year. Tesla (ticker:TSLA) was faring better Tuesday, with shares rising 3.7% to $1,046 in premarket trading.</p>\n<p>Of the 41 analysts surveyed by FactSet, 17 rate the stock at Buy or Overweight, 12 rate it a Hold, and 12 rate it a Sell. The average price target is $851.09.</p>\n<p>Tesla’s access to chips and batteries through vertical integration sets it apart from its competitors, helping the company cement market leadership with about 20% global EV share, the analyst said.</p>\n<p>“We’ve raised estimates sharply to reflect this undisputed leadership, however, current valuation fully reflects such steep curve,” Hummel wrote in a research note Tuesday.</p>\n<p>The title of Hummel’s research note on Tesla was: “Cementing leadership as EV market takes off: New $1,000 price target (from $725) – no rival to get even close to Tesla in 2022.”</p>\n<p>Hummel is forecasting Tesla’s car sales to grow from 894,000 in 2021 to 1.4 million in 2022, and reach 2.9 million by 2025, more than competitors&nbsp;BMW&nbsp;(BMW.DE) or&nbsp;Mercedes-Benz.He expects EVs in general to account for 50% of global car sales by 2030.</p>\n<p>A big part of Tesla’s advantage is the software’s scalability, which can drive a big revenue pool with even higher margins well beyond 2025, Hummel said.</p>\n<p>“Software is the next battleground in the global car industry, and no other carmaker is closer to monetize fully autonomous driving for everyday use, and the scalability of Tesla’s technology creates the biggest software-driven revenue opportunity in the industry,” he wrote.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock Price Target Raised to $1,000 at UBS. Here Is Why.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock Price Target Raised to $1,000 at UBS. Here Is Why.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-tsla-stock-price-target-raised-ubs-electric-vehicles-51638885474?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Tesla were rebounding Tuesday after UBS raised its price target on the stock, calling the electric-vehicle company the “undisputed leader” in the market.\nAnalyst Patrick Hummel increased his...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-tsla-stock-price-target-raised-ubs-electric-vehicles-51638885474?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-tsla-stock-price-target-raised-ubs-electric-vehicles-51638885474?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195364731","content_text":"Shares of Tesla were rebounding Tuesday after UBS raised its price target on the stock, calling the electric-vehicle company the “undisputed leader” in the market.\nAnalyst Patrick Hummel increased his price target to $1,000 from $725, saying global demand for electric vehicles will propel the company to continue beating expectations in 2022. Hummel maintained a Neutral rating on the stock.\nThe electric-vehicle manufacturer had a rough Monday, with the stock closing at $1,009.01, slipping dangerously close to its third bear market of the year. Tesla (ticker:TSLA) was faring better Tuesday, with shares rising 3.7% to $1,046 in premarket trading.\nOf the 41 analysts surveyed by FactSet, 17 rate the stock at Buy or Overweight, 12 rate it a Hold, and 12 rate it a Sell. The average price target is $851.09.\nTesla’s access to chips and batteries through vertical integration sets it apart from its competitors, helping the company cement market leadership with about 20% global EV share, the analyst said.\n“We’ve raised estimates sharply to reflect this undisputed leadership, however, current valuation fully reflects such steep curve,” Hummel wrote in a research note Tuesday.\nThe title of Hummel’s research note on Tesla was: “Cementing leadership as EV market takes off: New $1,000 price target (from $725) – no rival to get even close to Tesla in 2022.”\nHummel is forecasting Tesla’s car sales to grow from 894,000 in 2021 to 1.4 million in 2022, and reach 2.9 million by 2025, more than competitors BMW (BMW.DE) or Mercedes-Benz.He expects EVs in general to account for 50% of global car sales by 2030.\nA big part of Tesla’s advantage is the software’s scalability, which can drive a big revenue pool with even higher margins well beyond 2025, Hummel said.\n“Software is the next battleground in the global car industry, and no other carmaker is closer to monetize fully autonomous driving for everyday use, and the scalability of Tesla’s technology creates the biggest software-driven revenue opportunity in the industry,” he wrote.","news_type":1},"isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852888572,"gmtCreate":1635257254747,"gmtModify":1635257319078,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"right&nbsp;","listText":"right&nbsp;","text":"right","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852888572","repostId":"2178721405","repostType":4,"repost":{"id":"2178721405","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1635252117,"share":"https://www.laohu8.com/m/news/2178721405?lang=&edition=full","pubTime":"2021-10-26 20:41","market":"us","language":"en","title":"Missed Tesla? Here's The Next $1 Trillion Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2178721405","media":"Investors","summary":"The idea of an S&P 500 company hitting $1 trillion in market value used to seem impossible. But analysts insist another is on the way.","content":"<p>The idea of an S&amp;P 500 company hitting $1 trillion in market value used to seem impossible. But <b>Tesla</b> just did it — and analysts insist another is on the way.</p>\n<p>Analysts think <b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> should be the sixth S&amp;P 500 company valued at $1 trillion or more in 12 months or less, returning it to the trillion-dollar club. It would put the social networking giant in the same trillion-dollar league as <b>Apple</b>, <b>Microsoft</b>, <b>Alphabet</b>, <b>Amazon.com</b> and now Tesla.</p>\n<p>Shares of Facebook closed Monday at 328.69, down more than 14% from the 52-week high. That parked the company's valuation at $927 billion. But that was prior to the company late Monday topping third-quarter profit forecasts by 1.3% and jumping in after-hours trading to north of 337 a share. At this price, Facebook is worth $950 billion.</p>\n<p>It's only a matter of time until Facebook returns to the rarefied trillion-dollar air, though, say S&amp;P 500 analysts.</p>\n<h2>Trillion Dollar Redux For Facebook</h2>\n<p>Predicting Facebook will be a $1 trillion company is somewhat of an anticlimactic call.</p>\n<p>The company first closed above a trillion-dollar valuation back in July of this year. But since then, it's been on a rough run. Allegations of putting profit ahead of users' mental health, a high-profile outage and exposure to data limits at Apple knocked Facebook from its trillion-dollar perch. <b>Snap</b>'s recent disappointing third quarter and warning of problems tailoring social media ads on iPhones only fanned the worries.</p>\n<p>But analysts remain resolute on Facebook's future. They're calling for the stock to rally another 27% from Monday's close to 416.43 in 12 months, says data from S&amp;P Global Market Intelligence and MarketSmith. And if they're right, that would make Facebook a company valued at $1.17 billion. Should you buy Facebook stock now?</p>\n<p>Interestingly, if analysts are right, Facebook would supplant Tesla as the fifth most-valuable company in the S&amp;P 500. Analysts actually think Tesla's stock will drop 23% to 787.15. And if that's correct, it means Tesla would be worth just $779.3 billion, or a third less than what they think Facebook will be worth in 12 months. Should you buy Tesla stock now?</p>\n<h2>Who's Up In S&amp;P 500 After Facebook?</h2>\n<p>Facebook and Tesla might jockey for the trillion-dollar prize. But other than those two, are any other S&amp;P 500 stocks anywhere near a trillion? Nothing immediate.</p>\n<p>Warren Buffett's <b>Berkshire Hathaway</b> would appear next in line, as its market value is now $657.9 billion. Analysts, though, think even in 12 months time the company will be worth just $730.8 billion, falling shy of the trillion-dollar mark by nearly 40%. Also, it's not a particularly fast grower, so unlikely to surprise much to the upside. Analysts think Berkshire Hathaway's adjusted profit per share will only grow by 6.9% in 2022.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a></b> is a likely candidate in due time. The payment processing firm is already worth nearly $500 billion. And its adjusted profit per share is seen jumping 25% in 2022 to $7.26. Even so, analysts don't think it's going to happen anytime soon. Analysts are calling for the stock to inch up just 0.9% in 12 months.</p>\n<p>So it seems the world might need to be satisfied with five, or maybe six, trillion dollar companies for some time.</p>\n<h2>Analysts: The Most Valuable S&amp;P 500 Companies In The Future</h2>\n<p><i>Current and projected market values</i></p>\n<table>\n <thead>\n  <tr>\n   <th>Company</th>\n   <th>Ticker</th>\n   <th>Stock YTD % ch.</th>\n   <th>Market value now ($ trillions)</th>\n   <th>Analysts' 12-month market value target</th>\n   <th>Sector</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>Apple</td>\n   <td></td>\n   <td>12.0%</td>\n   <td>$2.5</td>\n   <td><b>$2.7</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Microsoft</td>\n   <td></td>\n   <td>38.5%</td>\n   <td>$2.3</td>\n   <td><b>$2.5</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Alphabet</td>\n   <td></td>\n   <td>56.8%</td>\n   <td>$1.8</td>\n   <td><b>$2.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Amazon.com</td>\n   <td></td>\n   <td>1.9%</td>\n   <td>$1.7</td>\n   <td><b>$2.1</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Facebook</td>\n   <td></td>\n   <td>20.3%</td>\n   <td>$0.9</td>\n   <td><b>$1.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Tesla</td>\n   <td></td>\n   <td>45.2%</td>\n   <td>$1.0</td>\n   <td><b>$0.8</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Berkshire Hathaway</td>\n   <td></td>\n   <td>25.5%</td>\n   <td>$0.7</td>\n   <td><b>$0.7</b></td>\n   <td>Financials</td>\n  </tr>\n  <tr>\n   <td>Visa</td>\n   <td></td>\n   <td>6.9%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Nvidia</td>\n   <td></td>\n   <td>77.4%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>JPMorgan Chase</td>\n   <td></td>\n   <td>34.5%</td>\n   <td>$0.5</td>\n   <td><b>$0.5</b></td>\n   <td>Financials</td>\n  </tr>\n </tbody>\n</table>\n<h5>Sources: IBD, S&amp;P Global Market Intelligence</h5>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Missed Tesla? Here's The Next $1 Trillion Company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMissed Tesla? Here's The Next $1 Trillion Company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-10-26 20:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>The idea of an S&amp;P 500 company hitting $1 trillion in market value used to seem impossible. But <b>Tesla</b> just did it — and analysts insist another is on the way.</p>\n<p>Analysts think <b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> should be the sixth S&amp;P 500 company valued at $1 trillion or more in 12 months or less, returning it to the trillion-dollar club. It would put the social networking giant in the same trillion-dollar league as <b>Apple</b>, <b>Microsoft</b>, <b>Alphabet</b>, <b>Amazon.com</b> and now Tesla.</p>\n<p>Shares of Facebook closed Monday at 328.69, down more than 14% from the 52-week high. That parked the company's valuation at $927 billion. But that was prior to the company late Monday topping third-quarter profit forecasts by 1.3% and jumping in after-hours trading to north of 337 a share. At this price, Facebook is worth $950 billion.</p>\n<p>It's only a matter of time until Facebook returns to the rarefied trillion-dollar air, though, say S&amp;P 500 analysts.</p>\n<h2>Trillion Dollar Redux For Facebook</h2>\n<p>Predicting Facebook will be a $1 trillion company is somewhat of an anticlimactic call.</p>\n<p>The company first closed above a trillion-dollar valuation back in July of this year. But since then, it's been on a rough run. Allegations of putting profit ahead of users' mental health, a high-profile outage and exposure to data limits at Apple knocked Facebook from its trillion-dollar perch. <b>Snap</b>'s recent disappointing third quarter and warning of problems tailoring social media ads on iPhones only fanned the worries.</p>\n<p>But analysts remain resolute on Facebook's future. They're calling for the stock to rally another 27% from Monday's close to 416.43 in 12 months, says data from S&amp;P Global Market Intelligence and MarketSmith. And if they're right, that would make Facebook a company valued at $1.17 billion. Should you buy Facebook stock now?</p>\n<p>Interestingly, if analysts are right, Facebook would supplant Tesla as the fifth most-valuable company in the S&amp;P 500. Analysts actually think Tesla's stock will drop 23% to 787.15. And if that's correct, it means Tesla would be worth just $779.3 billion, or a third less than what they think Facebook will be worth in 12 months. Should you buy Tesla stock now?</p>\n<h2>Who's Up In S&amp;P 500 After Facebook?</h2>\n<p>Facebook and Tesla might jockey for the trillion-dollar prize. But other than those two, are any other S&amp;P 500 stocks anywhere near a trillion? Nothing immediate.</p>\n<p>Warren Buffett's <b>Berkshire Hathaway</b> would appear next in line, as its market value is now $657.9 billion. Analysts, though, think even in 12 months time the company will be worth just $730.8 billion, falling shy of the trillion-dollar mark by nearly 40%. Also, it's not a particularly fast grower, so unlikely to surprise much to the upside. Analysts think Berkshire Hathaway's adjusted profit per share will only grow by 6.9% in 2022.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a></b> is a likely candidate in due time. The payment processing firm is already worth nearly $500 billion. And its adjusted profit per share is seen jumping 25% in 2022 to $7.26. Even so, analysts don't think it's going to happen anytime soon. Analysts are calling for the stock to inch up just 0.9% in 12 months.</p>\n<p>So it seems the world might need to be satisfied with five, or maybe six, trillion dollar companies for some time.</p>\n<h2>Analysts: The Most Valuable S&amp;P 500 Companies In The Future</h2>\n<p><i>Current and projected market values</i></p>\n<table>\n <thead>\n  <tr>\n   <th>Company</th>\n   <th>Ticker</th>\n   <th>Stock YTD % ch.</th>\n   <th>Market value now ($ trillions)</th>\n   <th>Analysts' 12-month market value target</th>\n   <th>Sector</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>Apple</td>\n   <td></td>\n   <td>12.0%</td>\n   <td>$2.5</td>\n   <td><b>$2.7</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Microsoft</td>\n   <td></td>\n   <td>38.5%</td>\n   <td>$2.3</td>\n   <td><b>$2.5</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Alphabet</td>\n   <td></td>\n   <td>56.8%</td>\n   <td>$1.8</td>\n   <td><b>$2.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Amazon.com</td>\n   <td></td>\n   <td>1.9%</td>\n   <td>$1.7</td>\n   <td><b>$2.1</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Facebook</td>\n   <td></td>\n   <td>20.3%</td>\n   <td>$0.9</td>\n   <td><b>$1.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Tesla</td>\n   <td></td>\n   <td>45.2%</td>\n   <td>$1.0</td>\n   <td><b>$0.8</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Berkshire Hathaway</td>\n   <td></td>\n   <td>25.5%</td>\n   <td>$0.7</td>\n   <td><b>$0.7</b></td>\n   <td>Financials</td>\n  </tr>\n  <tr>\n   <td>Visa</td>\n   <td></td>\n   <td>6.9%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Nvidia</td>\n   <td></td>\n   <td>77.4%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>JPMorgan Chase</td>\n   <td></td>\n   <td>34.5%</td>\n   <td>$0.5</td>\n   <td><b>$0.5</b></td>\n   <td>Financials</td>\n  </tr>\n </tbody>\n</table>\n<h5>Sources: IBD, S&amp;P Global Market Intelligence</h5>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","TSLA":"特斯拉","BRK.B":"伯克希尔B","AMZN":"亚马逊",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178721405","content_text":"The idea of an S&P 500 company hitting $1 trillion in market value used to seem impossible. But Tesla just did it — and analysts insist another is on the way.\nAnalysts think Facebook should be the sixth S&P 500 company valued at $1 trillion or more in 12 months or less, returning it to the trillion-dollar club. It would put the social networking giant in the same trillion-dollar league as Apple, Microsoft, Alphabet, Amazon.com and now Tesla.\nShares of Facebook closed Monday at 328.69, down more than 14% from the 52-week high. That parked the company's valuation at $927 billion. But that was prior to the company late Monday topping third-quarter profit forecasts by 1.3% and jumping in after-hours trading to north of 337 a share. At this price, Facebook is worth $950 billion.\nIt's only a matter of time until Facebook returns to the rarefied trillion-dollar air, though, say S&P 500 analysts.\nTrillion Dollar Redux For Facebook\nPredicting Facebook will be a $1 trillion company is somewhat of an anticlimactic call.\nThe company first closed above a trillion-dollar valuation back in July of this year. But since then, it's been on a rough run. Allegations of putting profit ahead of users' mental health, a high-profile outage and exposure to data limits at Apple knocked Facebook from its trillion-dollar perch. Snap's recent disappointing third quarter and warning of problems tailoring social media ads on iPhones only fanned the worries.\nBut analysts remain resolute on Facebook's future. They're calling for the stock to rally another 27% from Monday's close to 416.43 in 12 months, says data from S&P Global Market Intelligence and MarketSmith. And if they're right, that would make Facebook a company valued at $1.17 billion. Should you buy Facebook stock now?\nInterestingly, if analysts are right, Facebook would supplant Tesla as the fifth most-valuable company in the S&P 500. Analysts actually think Tesla's stock will drop 23% to 787.15. And if that's correct, it means Tesla would be worth just $779.3 billion, or a third less than what they think Facebook will be worth in 12 months. Should you buy Tesla stock now?\nWho's Up In S&P 500 After Facebook?\nFacebook and Tesla might jockey for the trillion-dollar prize. But other than those two, are any other S&P 500 stocks anywhere near a trillion? Nothing immediate.\nWarren Buffett's Berkshire Hathaway would appear next in line, as its market value is now $657.9 billion. Analysts, though, think even in 12 months time the company will be worth just $730.8 billion, falling shy of the trillion-dollar mark by nearly 40%. Also, it's not a particularly fast grower, so unlikely to surprise much to the upside. Analysts think Berkshire Hathaway's adjusted profit per share will only grow by 6.9% in 2022.\nVisa is a likely candidate in due time. The payment processing firm is already worth nearly $500 billion. And its adjusted profit per share is seen jumping 25% in 2022 to $7.26. Even so, analysts don't think it's going to happen anytime soon. Analysts are calling for the stock to inch up just 0.9% in 12 months.\nSo it seems the world might need to be satisfied with five, or maybe six, trillion dollar companies for some time.\nAnalysts: The Most Valuable S&P 500 Companies In The Future\nCurrent and projected market values\n\n\n\nCompany\nTicker\nStock YTD % ch.\nMarket value now ($ trillions)\nAnalysts' 12-month market value target\nSector\n\n\n\n\nApple\n\n12.0%\n$2.5\n$2.7\nInformation Technology\n\n\nMicrosoft\n\n38.5%\n$2.3\n$2.5\nInformation Technology\n\n\nAlphabet\n\n56.8%\n$1.8\n$2.2\nCommunication Services\n\n\nAmazon.com\n\n1.9%\n$1.7\n$2.1\nConsumer Discretionary\n\n\nFacebook\n\n20.3%\n$0.9\n$1.2\nCommunication Services\n\n\nTesla\n\n45.2%\n$1.0\n$0.8\nConsumer Discretionary\n\n\nBerkshire Hathaway\n\n25.5%\n$0.7\n$0.7\nFinancials\n\n\nVisa\n\n6.9%\n$0.6\n$0.6\nInformation Technology\n\n\nNvidia\n\n77.4%\n$0.6\n$0.6\nInformation Technology\n\n\nJPMorgan Chase\n\n34.5%\n$0.5\n$0.5\nFinancials\n\n\n\nSources: IBD, S&P Global Market Intelligence","news_type":1},"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}